MY205011A - Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof - Google Patents
Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereofInfo
- Publication number
- MY205011A MY205011A MYPI2020003575A MYPI2020003575A MY205011A MY 205011 A MY205011 A MY 205011A MY PI2020003575 A MYPI2020003575 A MY PI2020003575A MY PI2020003575 A MYPI2020003575 A MY PI2020003575A MY 205011 A MY205011 A MY 205011A
- Authority
- MY
- Malaysia
- Prior art keywords
- formula
- disease
- diabetes
- cardiac failure
- diabetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 | ||
| PCT/JP2019/003052 WO2019151274A1 (ja) | 2018-02-01 | 2019-01-30 | 含窒素複素環アミド化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY205011A true MY205011A (en) | 2024-09-27 |
Family
ID=67479787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020003575A MY205011A (en) | 2018-02-01 | 2019-01-30 | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10800784B2 (https=) |
| EP (1) | EP3747888A4 (https=) |
| JP (3) | JP7241556B2 (https=) |
| KR (1) | KR102725118B1 (https=) |
| CN (1) | CN111655692B (https=) |
| AR (1) | AR114237A1 (https=) |
| AU (1) | AU2019214048B2 (https=) |
| BR (1) | BR112020014177A2 (https=) |
| CA (1) | CA3090219A1 (https=) |
| CL (1) | CL2020002003A1 (https=) |
| CO (1) | CO2020009420A2 (https=) |
| IL (1) | IL276386B2 (https=) |
| MX (1) | MX2020008126A (https=) |
| MY (1) | MY205011A (https=) |
| PE (1) | PE20211273A1 (https=) |
| PH (1) | PH12020500613A1 (https=) |
| SA (1) | SA520412473B1 (https=) |
| SG (1) | SG11202006916SA (https=) |
| TW (1) | TWI803570B (https=) |
| WO (1) | WO2019151274A1 (https=) |
| ZA (1) | ZA202004548B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638377A (zh) | 2018-09-11 | 2021-04-09 | 日本烟草产业株式会社 | 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂 |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| HRP20241159T1 (hr) | 2020-02-07 | 2024-12-06 | Gasherbrum Bio, Inc. | Heterociklički agonisti za glp-1 |
| PL4116301T3 (pl) * | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
| CN116368140A (zh) * | 2020-09-10 | 2023-06-30 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| US20240025924A1 (en) * | 2021-03-23 | 2024-01-25 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Heterocycle substituted ketone derivative, and composition and medicinal use thereof |
| AU2022337617A1 (en) | 2021-09-01 | 2024-04-18 | Japan Tobacco Inc. | Nitrogen-containing tricyclic compound and pharmaceutical use thereof |
| CN120957993A (zh) | 2023-02-16 | 2025-11-14 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) * | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| CA2689930A1 (en) | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| CN103889996B (zh) * | 2011-06-27 | 2016-02-03 | 阿列科托斯治疗有限公司 | 选择性糖苷酶抑制剂及其用途 |
| WO2013074388A1 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| DK2858986T3 (da) | 2012-06-12 | 2019-11-25 | Chong Kun Dang Pharmaceutical Corp | Piperidinderivater som gpr119-agonister |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| BR112015022077A2 (pt) * | 2013-03-15 | 2017-07-18 | Japan Tobacco Inc | composto de pirazol-amida e usos medicinais do mesmo |
| US20150025120A1 (en) | 2013-07-01 | 2015-01-22 | Japan Tobacco Inc. | Pyrazole-alcohol compounds and pharmaceutical use thereof |
| US20150018403A1 (en) * | 2013-07-01 | 2015-01-15 | Japan Tobacco Inc. | Fluorene-amide compounds and pharmaceutical use thereof |
| GB201316823D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| ES2665148T3 (es) | 2013-12-17 | 2018-04-24 | Merck Patent Gmbh | Derivados de N1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piperidina como inhibidores de la piruvato deshidrogenasa quinasa |
| EP3328857B1 (en) | 2015-07-31 | 2019-08-14 | Merck Patent GmbH | Bicyclic heterocyclic derivatives |
| US11026936B2 (en) | 2016-03-29 | 2021-06-08 | Merck Patent Gmbh | Piperidinyl-propanone derivatives |
| CN109071490B (zh) * | 2016-04-28 | 2021-04-06 | 默克专利股份公司 | 哌啶基衍生物 |
| KR20190036549A (ko) * | 2016-07-29 | 2019-04-04 | 니뽄 다바코 산교 가부시키가이샤 | 피라졸-아미드 화합물의 제조 방법 |
| WO2018034918A1 (en) * | 2016-08-15 | 2018-02-22 | Merck Sharp & Dohme Corp. | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| PL4116301T3 (pl) * | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
| AU2022337617A1 (en) * | 2021-09-01 | 2024-04-18 | Japan Tobacco Inc. | Nitrogen-containing tricyclic compound and pharmaceutical use thereof |
-
2019
- 2019-01-30 AR ARP190100202A patent/AR114237A1/es unknown
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/ja not_active Ceased
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 KR KR1020207024426A patent/KR102725118B1/ko active Active
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/pt unknown
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/es unknown
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/zh active Active
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/es unknown
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/ja active Active
- 2019-01-30 MY MYPI2020003575A patent/MY205011A/en unknown
- 2019-01-30 TW TW108103504A patent/TWI803570B/zh active
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/ar unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/es unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/es unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/ja not_active Ceased
- 2023-09-05 US US18/460,821 patent/US20240300952A1/en not_active Abandoned
-
2024
- 2024-06-12 JP JP2024094812A patent/JP2024116307A/ja active Pending
-
2025
- 2025-02-13 US US19/052,425 patent/US20260070910A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205011A (en) | Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof | |
| RU2015144182A (ru) | Пиразоламидное соединение и его применения в медицине | |
| MX2019011782A (es) | Derivados de acido ciclilo-acetico sustituido para el tratamiento de enfermedades metabolicas. | |
| ZA202209620B (en) | Fused tricyclic compound and medicinal use thereof | |
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| JP2015508749A5 (https=) | ||
| MY201919A (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| EA202191286A1 (ru) | Ингибитор 15-pgdh | |
| JP2014518853A5 (https=) | ||
| JP2016041701A5 (https=) | ||
| JP2019131544A5 (https=) | ||
| PH12021550061A1 (en) | Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same | |
| MD4557C1 (ro) | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu | |
| HK1212688A1 (zh) | 吡啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途 | |
| PH12017502010A1 (en) | Process for the preparation of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninate monohydrochloride | |
| WO2015049698A3 (en) | Process for regorafenib | |
| ZA202402435B (en) | Nitrogen-containing tricyclic compound and pharmaceutical use thereof | |
| CL2024000633A1 (es) | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico. | |
| JP2016518428A5 (https=) | ||
| JP2016510805A5 (https=) | ||
| JP2014509622A5 (https=) | ||
| RU2018128304A (ru) | Пиразоламидное соединение и его применения в медицине | |
| RU2019114208A (ru) | Кристаллические формы 4-(2-((1r,2r)-2-гидроксициклогексиламино)бензотиазол-6-илокси)-n-метилпиколинамида | |
| RU2018131500A (ru) | Кристаллические модификации гидрохлорида n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина и солей n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина | |
| TH157552A (th) | องค์ประกอบทางเภสัชกรรมและวิธีสำหรับรักษาอาการฟุ้งพล่านแบบเฉียบพลัน |